Details for New Drug Application (NDA): 215959
✉ Email this page to a colleague
NDA 215959 describes LOSARTAN POTASSIUM, which is a drug marketed by Aiping Pharm Inc, Alembic Pharms Ltd, Apotex, Apotex Corp, Aurobindo Pharma, Chartwell Rx, Granules, Graviti Pharms, Hetero Labs Ltd V, Hikma, Hisun Pharm Hangzhou, Ipca Labs Ltd, Jubilant Cadista, Lupin Ltd, Macleods Pharms Ltd, Micro Labs, MSN, Mylan, Prinston Inc, Strides Pharma, Teva, Torrent Pharms, Unichem, Watson Labs, Zydus Pharms Usa Inc, and Teva Pharms, and is included in forty-two NDAs. It is available from forty-seven suppliers. Additional details are available on the LOSARTAN POTASSIUM profile page.
The generic ingredient in LOSARTAN POTASSIUM is hydrochlorothiazide; losartan potassium. There are thirty-two drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.
The generic ingredient in LOSARTAN POTASSIUM is hydrochlorothiazide; losartan potassium. There are thirty-two drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; losartan potassium profile page.
Summary for 215959
| Tradename: | LOSARTAN POTASSIUM |
| Applicant: | Granules |
| Ingredient: | losartan potassium |
| Patents: | 0 |
Pharmacology for NDA: 215959
| Mechanism of Action | Angiotensin 2 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 215959
Suppliers and Packaging for NDA: 215959
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| LOSARTAN POTASSIUM | losartan potassium | TABLET;ORAL | 215959 | ANDA | Granules India Ltd | 62207-741 | 62207-741-49 | 1000 TABLET in 1 BOTTLE (62207-741-49) |
| LOSARTAN POTASSIUM | losartan potassium | TABLET;ORAL | 215959 | ANDA | Granules India Ltd | 62207-741 | 62207-741-54 | 30 TABLET in 1 BOTTLE (62207-741-54) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 25MG | ||||
| Approval Date: | Feb 23, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 50MG | ||||
| Approval Date: | Feb 23, 2023 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 100MG | ||||
| Approval Date: | Feb 23, 2023 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
